Drug Profile
Beta alethine - Dovetail Technologies
Alternative Names: Alethine beta; Ax-101; Beta LT; BetathineLatest Information Update: 15 Jun 2021
Price :
$50
*
At a glance
- Originator University of New Mexico
- Developer LifeTime Pharmaceuticals
- Class Small molecules
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
- Discontinued Lymphoma; Macroglobulinaemia; Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 10 Apr 2021 Pharmacodynamics data from a preclinical study in solid tumours presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 01 Apr 2021 Preclinical trials in Solid tumours in USA (unspecified route), before April 2021
- 30 Apr 2002 LifeTime Pharmaceuticals has acquired all the intellectual property covering beta alethine from Dovetail